AC Immune S.A.

AC Immune (ACIU) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.

AC Immune announces financial and corporate updates for the quarter ended September 30, 2026, with positive progress across its wholly-owned pipeline.

SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.

AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson's disease.

AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for ACI-7104 in early-stage Parkinson's disease. Progress in the pipeline includes Takeda-partnered ACI-24 for prodromal Alzheimer's, triggering a $12M milestone and showing antibody responses at all dose levels. Brain-penetrant NLRP3 inhibitor ACI-19764 advances, with phase 1/1b initial data at the end of 2026 and final data in the 1st half of 2027, targeting neuroinflammatory and metabolic disorders.

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated Strong immunogenicity demonstrated, with 100% response rate after three immunizations Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement Discussions with FDA regarding future development path planned for early 2027 AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below Lausanne, Switzerland, September 23, 2026 –…

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.